Related Experiment Video

Updated: Jul 17, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.0K

Effect of Liraglutide on Cardiac Function in Individuals With Type 2 Diabetes: A Meta-Analysis

Hasnaat Haroon1, Ajanta Kumari2, Bihari Lal3

  • 1Internal Medicine, Medical College, Foundation University Medical College, Islamabad, PAK.

Cureus
|August 30, 2023
PubMed

Insights

Liraglutide significantly improved diastolic cardiac function in individuals with type 2 diabetes by reducing E/A and E/Ea ratios. However, it did not show significant effects on systolic cardiac function metrics like LVEF or cardiac output.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes is associated with impaired cardiac function.
  • Liraglutide, a glucagon-like peptide-1 receptor agonist, is used for type 2 diabetes management.
  • Understanding liraglutide's impact on cardiac function is crucial for patient care.

Purpose of the Study:

  • To evaluate the effect of liraglutide on cardiac function in patients with type 2 diabetes.
  • To conduct a meta-analysis of existing studies on liraglutide and cardiac function.

Main Methods:

  • A systematic search of PubMed, Google Scholar, and Cochrane Library was performed.
  • Included observational and randomized controlled trials comparing liraglutide with placebo or other drugs.
  • Assessed diastolic function (E/A, E/Ea ratios) and systolic function (stroke volume, LVEF, cardiac output, cardiac index).

Main Results:

  • Liraglutide significantly reduced the E/A ratio (MD: -0.22, p=0.008) and E/Ea ratio (MD: -0.76, p=0.02).
  • These findings suggest a potential clinical benefit on ventricular diastolic function.
  • No significant impact was observed on left ventricular ejection fraction (LVEF), cardiac output, cardiac index, or stroke volume.

Conclusions:

  • Liraglutide demonstrates a beneficial effect on diastolic cardiac function in individuals with type 2 diabetes.
  • Liraglutide does not appear to significantly improve systolic cardiac function in this population.
  • Further research may explore long-term cardiac outcomes with liraglutide therapy.

Keywords:
diastolic cardiac functionliraglutidemeta-analysissystolic cardiac functiontype 2 diabetes

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

221
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

656

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
184
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
310